Puma Biotechnology Inc - Company Profile
Powered by 
All the sales intelligence you need on Puma Biotechnology Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Puma Biotechnology Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Puma Biotechnology Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Puma Biotechnology Catalyst Calendar
Proactively evaluate Puma Biotechnology Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Puma Biotechnology Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 30 Jun 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 27 May 2020 | Phase II Trial Results | AbbVie Inc; Ambrx Biopharma Inc; Amgen Inc; Byondis BV; Dynavax Technologies Corp; Eisai Co Ltd; Eli Lilly and Co; Foundation for the National Institutes of Health Inc; G1 Therapeutics Inc; Genentech USA Inc; IQVIA Holdings Inc; Johnson & Johnson; Madrigal Pharmaceuticals Inc; Merck & Co Inc; Pfizer Inc; Plexxikon Inc; Puma Biotechnology Inc; Quantum Leap Health Care Collaborative; Regeneron Pharmaceuticals Inc; The Safeway Foundation | 4523; ABBV; AMAM; AMGN; DVAX; GTHX; IQV; JNJ; LLY; MDGL; MRK; PBYI; PFE; REGN | amcenestrant; ARX-788; cemiplimab; doxorubicin; encequidar mesylate + paclitaxel; fianlimab; ganitumab; lasofoxifene tartrate; MK-2206; neratinib; pembrolizumab; pexidartinib hydrochloride; SD-101; talazoparib; trastuzumab duocarmazine; trebananib; trilaciclib; veliparib ER | Oncology | Angiosarcoma; Breast Cancer; Breast Tumor; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Metastatic Breast Cancer; Triple-Negative Breast Cancer (TNBC) | Company Press Release |
| 26 Feb 2020 | PDUFA | Puma Biotechnology Inc | PBYI | neratinib | Oncology | Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
| 31 Dec 2019 | Phase II Trial Results | Puma Biotechnology Inc; U.S. Department of Defence | PBYI | neratinib | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer